Effect of tissue shipping on plasma cell isolation, viability, and RNA integrity in the context of a centralized good laboratory practice-certified tissue banking facility

Gregory J. Ahmann, Joo Chng Wee, Kimberly J. Henderson, Tammy L. Price-Troska, Roberta W. DeGoey, Michael M. Timm, Angela Dispenzieri, Philip R. Greipp, Alicia Sable-Hunt, Peter Leif Bergsagel, Rafael Fonseca

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The Multiple Myeloma Research Consortium has established a tissue bank for the deposition of bone marrow samples from patients with multiple myeloma to be mailed and processed under good laboratory practices. To date, over 1,000 samples have been collected. At this time, limited information is available on shipped bone marrow aspirates in regards to cell viability, yield, purity, and subsequent RNA yield and quality. To test these determinants, we did a pilot study on behalf of the Multiple Myeloma Research Consortium where samples were drawn at Mayo Clinic Rochester (MCR) pooled and split into two equal aliquots. One-half of each sample was processed following good laboratory practices compliant standard operating procedures, immediately after sample procurement, at MCR. The CD138+ cells were stored at -80°C as a Trizol lysate. The other half of the aspirate was sent overnight to Mayo Clinic Scottsdale where they were processed using identical standard operating procedures. The RNA was extracted and analyzed in a single batch at MCR. At both locations, samples were assayed for the following quality determinants: Viability was assessed using a three-color flow cytometric method (CD45, CD38, and 7-AAD). Cell counts were done to determine plasma cell recovery and post-sort purity determined by means of a slide-based immunofluorescent assay. RNA recovery and integrity was assessed using the Agilent Bioanalyzer. Lastly, gene expression profiles were compared to determine the signature emanating from the shipment of samples. Despite minor differences, our results suggest that shipment of samples did not significantly affect these quality determinants in aggregate.

Original languageEnglish (US)
Pages (from-to)666-673
Number of pages8
JournalCancer Epidemiology Biomarkers and Prevention
Volume17
Issue number3
DOIs
StatePublished - Mar 2008

Fingerprint

Tissue Banks
Cell Separation
Plasma Cells
Multiple Myeloma
Cell Survival
RNA
Bone Marrow
Transcriptome
Research
Color
Cell Count

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Effect of tissue shipping on plasma cell isolation, viability, and RNA integrity in the context of a centralized good laboratory practice-certified tissue banking facility. / Ahmann, Gregory J.; Wee, Joo Chng; Henderson, Kimberly J.; Price-Troska, Tammy L.; DeGoey, Roberta W.; Timm, Michael M.; Dispenzieri, Angela; Greipp, Philip R.; Sable-Hunt, Alicia; Bergsagel, Peter Leif; Fonseca, Rafael.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 17, No. 3, 03.2008, p. 666-673.

Research output: Contribution to journalArticle

Ahmann, Gregory J. ; Wee, Joo Chng ; Henderson, Kimberly J. ; Price-Troska, Tammy L. ; DeGoey, Roberta W. ; Timm, Michael M. ; Dispenzieri, Angela ; Greipp, Philip R. ; Sable-Hunt, Alicia ; Bergsagel, Peter Leif ; Fonseca, Rafael. / Effect of tissue shipping on plasma cell isolation, viability, and RNA integrity in the context of a centralized good laboratory practice-certified tissue banking facility. In: Cancer Epidemiology Biomarkers and Prevention. 2008 ; Vol. 17, No. 3. pp. 666-673.
@article{7cce37ad59bb498f812f8098779be4cd,
title = "Effect of tissue shipping on plasma cell isolation, viability, and RNA integrity in the context of a centralized good laboratory practice-certified tissue banking facility",
abstract = "The Multiple Myeloma Research Consortium has established a tissue bank for the deposition of bone marrow samples from patients with multiple myeloma to be mailed and processed under good laboratory practices. To date, over 1,000 samples have been collected. At this time, limited information is available on shipped bone marrow aspirates in regards to cell viability, yield, purity, and subsequent RNA yield and quality. To test these determinants, we did a pilot study on behalf of the Multiple Myeloma Research Consortium where samples were drawn at Mayo Clinic Rochester (MCR) pooled and split into two equal aliquots. One-half of each sample was processed following good laboratory practices compliant standard operating procedures, immediately after sample procurement, at MCR. The CD138+ cells were stored at -80°C as a Trizol lysate. The other half of the aspirate was sent overnight to Mayo Clinic Scottsdale where they were processed using identical standard operating procedures. The RNA was extracted and analyzed in a single batch at MCR. At both locations, samples were assayed for the following quality determinants: Viability was assessed using a three-color flow cytometric method (CD45, CD38, and 7-AAD). Cell counts were done to determine plasma cell recovery and post-sort purity determined by means of a slide-based immunofluorescent assay. RNA recovery and integrity was assessed using the Agilent Bioanalyzer. Lastly, gene expression profiles were compared to determine the signature emanating from the shipment of samples. Despite minor differences, our results suggest that shipment of samples did not significantly affect these quality determinants in aggregate.",
author = "Ahmann, {Gregory J.} and Wee, {Joo Chng} and Henderson, {Kimberly J.} and Price-Troska, {Tammy L.} and DeGoey, {Roberta W.} and Timm, {Michael M.} and Angela Dispenzieri and Greipp, {Philip R.} and Alicia Sable-Hunt and Bergsagel, {Peter Leif} and Rafael Fonseca",
year = "2008",
month = "3",
doi = "10.1158/1055-9965.EPI-07-2649",
language = "English (US)",
volume = "17",
pages = "666--673",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Effect of tissue shipping on plasma cell isolation, viability, and RNA integrity in the context of a centralized good laboratory practice-certified tissue banking facility

AU - Ahmann, Gregory J.

AU - Wee, Joo Chng

AU - Henderson, Kimberly J.

AU - Price-Troska, Tammy L.

AU - DeGoey, Roberta W.

AU - Timm, Michael M.

AU - Dispenzieri, Angela

AU - Greipp, Philip R.

AU - Sable-Hunt, Alicia

AU - Bergsagel, Peter Leif

AU - Fonseca, Rafael

PY - 2008/3

Y1 - 2008/3

N2 - The Multiple Myeloma Research Consortium has established a tissue bank for the deposition of bone marrow samples from patients with multiple myeloma to be mailed and processed under good laboratory practices. To date, over 1,000 samples have been collected. At this time, limited information is available on shipped bone marrow aspirates in regards to cell viability, yield, purity, and subsequent RNA yield and quality. To test these determinants, we did a pilot study on behalf of the Multiple Myeloma Research Consortium where samples were drawn at Mayo Clinic Rochester (MCR) pooled and split into two equal aliquots. One-half of each sample was processed following good laboratory practices compliant standard operating procedures, immediately after sample procurement, at MCR. The CD138+ cells were stored at -80°C as a Trizol lysate. The other half of the aspirate was sent overnight to Mayo Clinic Scottsdale where they were processed using identical standard operating procedures. The RNA was extracted and analyzed in a single batch at MCR. At both locations, samples were assayed for the following quality determinants: Viability was assessed using a three-color flow cytometric method (CD45, CD38, and 7-AAD). Cell counts were done to determine plasma cell recovery and post-sort purity determined by means of a slide-based immunofluorescent assay. RNA recovery and integrity was assessed using the Agilent Bioanalyzer. Lastly, gene expression profiles were compared to determine the signature emanating from the shipment of samples. Despite minor differences, our results suggest that shipment of samples did not significantly affect these quality determinants in aggregate.

AB - The Multiple Myeloma Research Consortium has established a tissue bank for the deposition of bone marrow samples from patients with multiple myeloma to be mailed and processed under good laboratory practices. To date, over 1,000 samples have been collected. At this time, limited information is available on shipped bone marrow aspirates in regards to cell viability, yield, purity, and subsequent RNA yield and quality. To test these determinants, we did a pilot study on behalf of the Multiple Myeloma Research Consortium where samples were drawn at Mayo Clinic Rochester (MCR) pooled and split into two equal aliquots. One-half of each sample was processed following good laboratory practices compliant standard operating procedures, immediately after sample procurement, at MCR. The CD138+ cells were stored at -80°C as a Trizol lysate. The other half of the aspirate was sent overnight to Mayo Clinic Scottsdale where they were processed using identical standard operating procedures. The RNA was extracted and analyzed in a single batch at MCR. At both locations, samples were assayed for the following quality determinants: Viability was assessed using a three-color flow cytometric method (CD45, CD38, and 7-AAD). Cell counts were done to determine plasma cell recovery and post-sort purity determined by means of a slide-based immunofluorescent assay. RNA recovery and integrity was assessed using the Agilent Bioanalyzer. Lastly, gene expression profiles were compared to determine the signature emanating from the shipment of samples. Despite minor differences, our results suggest that shipment of samples did not significantly affect these quality determinants in aggregate.

UR - http://www.scopus.com/inward/record.url?scp=41549159202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41549159202&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-07-2649

DO - 10.1158/1055-9965.EPI-07-2649

M3 - Article

C2 - 18349285

AN - SCOPUS:41549159202

VL - 17

SP - 666

EP - 673

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 3

ER -